The inhibition of poly(ADP‐ribose) polymerases (PARPs) and ataxia telangiectasia and Rad3‐related (ATR) would be an alternative approach for cancer treatments. The aim of this study is to investigate the synergy of the different combinations of PARP inhibitors (olaparib, talazoparib, or veliparib) and ATR inhibitor AZD6738. A drug combinational synergy screen that combines olaparib, talazoparib, or veliparib with AZD6738 was performed to identify the synergistic interaction, and the combination index was calculated to verify synergy. TK6 isogenic cell lines with defects in different DNA repair genes were used as a model. Cell cycle analysis, micronucleus induction, and focus formation assays of serine‐139 phosphorylation of the histone variant H2AX demonstrated that AZD6738 diminished G2/M checkpoint activation induced by PARP inhibitors and allowed DNA damage‐containing cells to continue dividing, leading to greater increases in micronuclei as well as double‐strand DNA breaks in mitotic cells. We also found that AZD6738 was likely to potentiate cytotoxicity of PARP inhibitors in homologous recombination repair deficiency cell lines. AZD6738 sensitized more genotypes of DNA repair‐deficient cell lines to talazoparib than to olaparib and veliparib, respectively. The combinational approach of PARP and ATR inhibition to enhance response to PARP inhibitors could expand the utility of PARP inhibitors to cancer patients without BRCA1/2 mutations.
Cancer is the leading cause of death worldwide, resulting in the mortality of more than 10 million people in 2020, according to Global Cancer Statistics 2020. A potential cancer therapy involves targeting the DNA repair process by inhibiting PARP-1. In this study, classification models were constructed using a non-redundant set of 2018 PARP-1 inhibitors. Briefly, compounds were described by 12 fingerprint types and built using the random forest algorithm concomitant with various sampling approaches. Results indicated that PubChem with an oversampling approach yielded the best performance, with a Matthews correlation coefficient > 0.7 while also affording interpretable molecular features. Moreover, feature importance, as determined from the Gini index, revealed that the aromatic/cyclic/heterocyclic moiety, nitrogen-containing fingerprints, and the ether/aldehyde/alcohol moiety were important for PARP-1 inhibition. Finally, our predictive model was deployed as a web application called PARP1pred and is publicly available at https://parp1pred.streamlitapp.com, allowing users to predict the biological activity of query compounds using their SMILES notation as the input. It is anticipated that the model described herein will aid in the discovery of effective PARP-1 inhibitors.
Recent developments in chemotherapy focus on target-specific mechanisms, which occur only in cancer cells and minimize the effects on normal cells. DNA damage and repair pathways are a promising target in the treatment of cancer. In order to identify novel compounds targeting DNA repair pathways, two key proteins, 53BP1 and RAD54L, were tagged with fluorescent proteins as indicators for two major double strand break (DSB) repair pathways: non-homologous end-joining (NHEJ) and homologous recombination (HR). The engineered biosensor cells exhibited the same DNA repair properties as the wild type. The biosensor cells were further used to investigate the DNA repair activities of natural biological compounds. An extract from Phyllosticta sp., the endophyte isolated from the medicinal plant Garcinia cowa Roxb. ex Choisy, was tested. The results showed that the crude extract induced DSB, as demonstrated by the increase in the DNA DSB marker γH2AX. The damaged DNA appeared to be repaired through NHEJ, as the 53BP1 focus formation in the treated fraction was higher than in the control group. In conclusion, DNA repair-based biosensors are useful for the preliminary screening of crude extracts and biological compounds for the identification of potential targeted therapeutic drugs.
1 March 2026 in Computational and Structural Biotechnology Journal
Poly(adenosine diphosphate-ribose) polymerase 1 (PARP1) is a pivotal target for treating homologous recombination-deficient cancers through the mechanism of synthetic lethality. While machine learning has accelerated the identification of novel inhibitors, many models lack experimental validation and high-resolution mechanistic insights. In this study, we evaluated the predictive robustness of the PARP1pred model using a hierarchical pipeline. Initial bioactivity predictions for candidates in unseen chemical space were validated through biochemical and cellular sensitivity assays using a panel of isogenic TK6 cell lines. Subsequently, molecular docking, 100-ns molecular dynamics simulations, and molecular mechanics Poisson–Boltzmann surface area (MM-PBSA) energetic analysis were performed to provide a structural and thermodynamic rationale for the observed inhibitory potencies. The workflow successfully identified ZINC49069486 as a highly potent nanomolar lead that induced selective synthetic lethality in BRCA1-deficient cells. Crucially, the pipeline correctly classified ZINC67913374 as biologically inactive [median inhibitory concentration (IC 50 ) > 100 μM], successfully identifying a false positive previously proposed in the literature as a potential inhibitor. MM-PBSA analysis revealed that the inactivity of ZINC67913374 was driven by an excessive polar solvation penalty that outweighed its favorable docking score. While ZINC98208034 and ZINC8793749 showed moderate enzymatic inhibition, they failed to induce a synthetic lethality response. These results confirm that the PARP1pred-driven hierarchical framework effectively prioritizes experimentally validated lead compound while filtering out deceptive computational hits, providing an accessible and robust strategy for PARP1 inhibitor discovery.
About Me
Research Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand
Research Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand